BTK and aneurysmal bone cyst: While MYD88/CD79B double-mutant ABC might be amenable to targeted therapy by BTK inhibitors such as ibrutinib, further studies are needed to define the best therapeutic strategy for isolated CD79B or MYD88-mutant DLBCLs.